Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1

被引：19

作者：

Dahm A.E.A. ^{[1
,2
]}

Iversen N. ^{[3
]}

Birkenes B. ^{[3
]}

Ree A.H. ^{[4
,5
]}

Sandset P.M. ^{[1
,2
]}

机构：

[1] Department of Haematology, Ullevål University Hospital

[2] Faculty Division Ullevål, University of Oslo

[3] Department of Medical Genetics, Ullevaal University Hospital

[4] Department of Tumor Biology, Rikshospitalet-Radiumhospitalet Medical Center

[5] Faculty Division Rikshospitalet-Radiumhospitalet, University of Oslo, Oslo

来源：

BMC Cardiovascular Disorders | / 6卷 / 1期

关键词：

Estrogen Receptor; Tamoxifen; Raloxifene; Fulvestrant; Estrogen Receptor Ligand;

D O I：

10.1186/1471-2261-6-40

中图分类号：

学科分类号：

摘要：

Background: Hormone therapy, oral contraceptives, and tamoxifen increase the risk of thrombotic disease. These compounds also reduce plasma content of tissue factor pathway inhibitor-1 (TFPI), which is the physiological inhibitor of the tissue factor pathway of coagulation. The current aim was to study if estrogens and estrogen receptor (ER) modulators may inhibit TFPI production in cultured endothelial cells and, if so, identify possible mechanisms involved. Methods: Human endothelial cell cultures were treated with 17β-estradiol (E2), 17α-ethinylestradiol (EE2), tamoxifen, raloxifene, or fulvestrant. Protein levels of TFPI in cell media and cell lysates were measured by an enzyme-linked immunosorbent assay, and TFPI mRNA levels were assessed by quantitative PCR. Expression of ERα was analysed by immunostaining. Results: All compounds (each in a concentration of 10 nM) reduced TFPI in cell medium, by 34% (E2), 21% (EE2), 16% (tamoxifen), and 28% (raloxifene), respectively, with identical inhibitory effects on cellular TFPI levels. Expression of TFPI mRNA was principally unchanged. Treatment with fulvestrant, which was also associated with down-regulation of secreted TFPI (9% with 10 nM land 26% with 1000 nM), abolished the TFPI-inhibiting effect of raloxifene, but not of the other compounds. Notably, the combination of 1000 nM fulvestrant and 10 nM raloxifene increased TFPI secretion, and, conversely, 10 nM of either tamoxifen or raloxifene seemed to partly (tamoxifen) or fully (raloxifene) counteract the inhibitory effect of 1000 nM fulvestrant. The cells did not express the regular nuclear 66 kDa ERα, but instead a 45 kDa ERα, which was not regulated by estrogens or ER modulators. Conclusion: E2, EE2, tamoxifen, raloxifene, and fulvestrant inhibited endothelial production of TFPI by a mechanism apparently independent of TFPI transcription. © 2006 Dahm et al; licensee BioMed Central Ltd.

引用

共 46 条

[1]

Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S., Risk of venous thromboembolism in users of hormone replacement therapy, Lancet, 348, pp. 977-980, (1996)

[2]

Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., Willett W.C., Hennekens C.H., Prospective study of exogenous hormones and risk of pulmonary embolism in women, Lancet, 348, pp. 983-987, (1996)

[3]

Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M., Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens, Lancet, 348, pp. 981-983, (1996)

[4]

Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset P.M., Increased risk of recurrent venous thromboembolism during hormone replacement therapy - Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET), Thromb Haemost, 84, pp. 961-967, (2000)

[5]

Koster T., Small R.A., Rosendaal F.R., Helmerhorst F.M., Oral contraceptives and venous thromboembolism: A quantitative discussion of the uncertainties, J Intern Med, 238, pp. 31-37, (1995)

[6]

Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study, Lancet, 346, pp. 1575-1582, (1995)

[7]

Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., Jordan V.C., The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation, JAMA, 281, pp. 2189-2197, (1999)

[8]

Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study, J Natl Cancer Inst, 90, pp. 1371-1388, (1998)

[9]

Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial, JAMA, 288, pp. 321-333, (2002)

[10]

Kemmeren J.M., Tanis B.C., van den Bosch M.A., Bollen E.L., Helmerhorst F.M., van der Graaf Y., Rosendaal F.R., Algra A., Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke, Stroke, 33, pp. 1202-1208, (2002)

← 1 2 3 4 5 →